	US 11,891,634 B2
	PDE5A destabilizing domains
Thomas J. Wandless, Stanford, CA (US); Ling-Chun Chen, Stanford, CA (US); and Yusaku Miyamae, Ibaraki (JP)
Assigned to THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, Stanford, CA (US)
Appl. No. 16/625,644
Filed by The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
PCT Filed Jun. 22, 2018, PCT No. PCT/US2018/039096 § 371(c)(1), (2) Date Dec. 20, 2019, PCT Pub. No. WO2018/237323, PCT Pub. Date Dec. 27, 2018.
Claims priority of provisional application 62/524,384, filed on Jun. 23, 2017.
Prior Publication US 2020/0123514 A1, Apr. 23, 2020
Int. Cl. C12N 9/00 (2006.01); C12N 15/62 (2006.01); C12N 15/10 (2006.01); C12N 9/16 (2006.01); C07K 14/435 (2006.01)

CPC C12N 9/16 (2013.01) [C07K 14/435 (2013.01); C12N 15/1055 (2013.01); C12N 15/62 (2013.01); C12Y 301/04017 (2013.01); C07K 2319/70 (2013.01)]

2 Claims

1. A conditional protein stability system, comprising:

a nucleic acid sequence encoding a fusion protein comprising a protein of interest fused in-frame to a single-protein, ligand dependent destabilizing domain wherein the ligand dependent destabilizing domain comprises SEQ ID NO: 19 (encoded by SEQ ID NO: 36); and

a ligand, wherein the ligand is Sildenafil or Vardenafil,

wherein upon introduction of the nucleic acid sequence to a cell,

the fusion protein is expressed, and

wherein degradation of the protein of interest is decreased upon administration of the ligand.